Clinical trials: Resected Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
OSCAR I STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic…
- Trial name
- NCT06481397
- Testing
- ONCObind (Onco-Seraph) 100 Filter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExThera Medical Corporation
Pancreatic Adenocarcinoma
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
- Trial name
- NCT01839799
- Testing
- Gemcitabine, Abraxane, FOLFIRINOX
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis. Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local…
- Trial name
- TMpE (NCT07148830)
- Testing
- Total Mesopancreas Excision (TMpE) (as part of Pancreaticoduodenectomy)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Minia University
Adenocarcinomas of the Pancreas
Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma
In patients with peritoneal metastases of colorectal cancer could be a radical removal of all tumor foci a significantly improved survival compared to a sole systemic chemotherapy are additionally achieved by a hyperthermic…
- Trial name
- PanHIPEC (NCT02863471)
- Testing
- Gemcitabine
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital Tuebingen
Pancreatic Cancer
Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer
The purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy has on resected pancreatic cancer.
- Trial name
- PC03 (NCT01553019)
- Testing
- Proton radiation, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies.
- Conditions
- Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-5 (NCT06384560)
- Testing
- Pembrolizumab, Folfirinox, SABR
- Where
- 4 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Amsterdam UMC, location VUmc
Pancreatic Cancer
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells.
- Trial name
- NCT00059826
- Testing
- interferon-alfa-2b, cisplatin, 5-fluorouracil
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
- Trial name
- NCT06913218
- Testing
- AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Pancreatic Ductal Adenocarcinoma (PDAC), NGS Monitor MRD
ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)
Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years.
- Trial name
- K4CARE-PDAC (NCT07597252)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Pancreatic Ductal Adenocarcinoma
Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma
More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low.
- Trial name
- NCT06344299
- Testing
- potential predictors
- Where
- China
- Volunteers
- 5,302 people
- Sponsor
- Fudan University
Pancreatic Cancer
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003216
- Testing
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- Radiation Therapy Oncology Group
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Pancreatic cancer represents the most lethal of the common malignancies with a 5-year survival rate of less than 5%. For patients who are eligible for potentially curative resection, despite mortality and morbidity rates after…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT02005419
- Testing
- Gemcitabine, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xian-Jun Yu
Pancreas Neoplasms, Liver Metastasis
Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases
The study focuses on patients with synchronous liver metastasis from pancreatic adenocarcinoma that underwent both pancreatic and liver resection.
- Conditions
- Pancreas Neoplasms, Liver Metastasis, Pancreas Ductal Adenocarcinoma, Surgery of the Pancreatic Head
- Trial name
- NCT06980792
- Testing
- Pancreatectomy and liver resection, Chemotherapy
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Carcinoma, Pancreatic Ductal
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis.
- Trial name
- PF-BARNA (NCT05489458)
- Testing
- Resection, No Resection
- Volunteers
- 100 people
- Sponsor
- BUSQUETS, JULI
Resectable Pancreatic Adenocarcinoma
Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer
This study intends to design the prospective, exploratory, single center clinical study, using targeted EGFR fluorescence imaging agent (anti-EGFR-IR800CW) and fluorescent navigation technology, in its lymph node tracing…
- Trial name
- CISPD-6 (NCT06168552)
- Testing
- Injection of fluorescent developer (anti-EGFR-IR800CW)
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pancreatic Adenocarcinoma
Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the pharmacokinetics (PK) of adjuvant capecitabine in patients who have undergone proximal pancreatico-duodenectomy.
- Trial name
- NCT00854477
- Testing
- capecitabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Pancreatic Neoplasms
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes after curative resection.
- Trial name
- NCT02754180
- Testing
- Gemcitabine, TS-1 with radiation
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Surgery, Liver Tumor
Evaluation of Resection Techniques for Pancreatic Tumors
The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.
- Conditions
- Surgery, Liver Tumor, Pancreas Tumor
- Trial name
- NCT05128890
- Testing
- Resection techniques for pancreatic and liver tumors
- Where
- United States
- Volunteers
- 431 people
- Sponsor
- Methodist Health System
Gastrinoma, Glucagonoma
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases
- Trial name
- NCT02031536
- Testing
- everolimus
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group